Basic Information
| LncRNA/CircRNA Name | TP53TG1 |
| Synonyms | TP53TG1, LINC00096, NCRNA00096, P53TG1, P53TG1-D, TP53AP1 |
| Region | GRCh38_7:87325225-87345515 |
| Ensemble | ENSG00000182165 |
| Refseq | NR_015381 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, luciferase reporter assay, RIP, in vitro knockdown etc. |
| Sample | cell line (HBE, A549), NSCLC tissue |
| Expression Pattern | down-regulated |
| Function Description | TP53TG1 level was downregulated in NSCLC tissues and cell lines.Upregulated TP53TG1 enhanced cisplatin sensitivity and apoptosis of A549/DDP cells,while TP53TG1 depletion inhibited cisplatin sensitivity and apoptosis of A549 cells.TP53TG1 suppressed miR-18a expression in A549 cells.Moreover,TP53TG1-mediated enhancement effect on cisplatin sensitivity was abated following the restoration of miR-18a expression in A549/DDP cells, while si-TP53TG1-induced decrease of cisplatin sensitivity and apoptosis was counteracted by miR-18a inhibitor in A549 cells. Furthermore, TP53TG1 promoted PTEN expression via inhibiting miR-18a.Finally,TP53TG1 sensitized NSCLC cells to cisplatin in vivo. |
| Pubmed ID | 29588850 |
| Year | 2018 |
| Title | TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18a/PTEN axis. |
External Links
| Links for TP53TG1 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |